Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: uncertainty as March and Q1 come to a close

March 31, 2022 7:43am

Risks are elevated with no clear path evident like a minefield!

Pre-open indications: 2 SELLs, 9 BUYs and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Just the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.13% (-47 points), S&P futures are DOWN -0.08% (-3.50 points) and NASDAQ futures are UP +0.09% (+14 points)

Stock futures are slipping in pre-open trading Thursday as the month and quarter come to a close,

European markets are being swept-off their feet by global geopolitical and economic uncertainty after Russia’s invasion of Ukraine,

Asia-Pacific markets were mixed and unpredictable.

Henry’omics:

Volatility pricing looms over equities … the major indexes retreated modestly Wednesday amid a strong stock market rally since March 14.

The S&P 500 and Nasdaq are on pace to finish the month up about 5% each, while the Dow is nearly 4% higher in March.

For Q1, the Dow and S&P 500 are both down about 3% and the Nasdaq is off more than 7%.

Economic Data Docket: The Commerce Department will release inflation data as part of the February income and spending report. The personal consumptions expenditures price index, the Fed's favorite inflation gauge, is expected to show a 6.4% gain vs. a year earlier. Core PCE inflation is seen hitting 5%.

RegMed Investors’ (RMi) closing bell: “the impact of doubts about the strength of a recent market rebound. Tuesday’s headwinds decreased the upsides while macro elements slowly infect sentiment.” … https://www.regmedinvestors.com/articles/12367

Ebb and flow –

· March – 12 negative and 10 positive closes

· February stats: 11 negative, 8 positive closes and 1 holiday

· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... (VSTM, BCLI and ADVM) 34 total to date

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS, POSSIBILITIES and POTENTIALS …

BUY, oversold that are poised to appreciate:

Agenus (AGEN -$0.070 a positive +$0.02 or +0.76% pre-open indication,
Applied Genetic Technologies (AGTC) closed down -$0.01 with a positive +$0.05 or +4.50% pre-open indication.
AxoGen (AXGN) closed down -$0.08 with a positive +$0.67 or +8.28% pre-open indication.
Caribou Biosciences (CRBU) closed down -$0.20 after Tuesday’s +0.11 after Monday’s +$0.12 with a positive +$0.45 or +4.86% pre-open indication.
Beam Therapeutics (BEAM closed down -$2.57 after Tuesday’s +$2.97 with a +$1.55 or +2.61% pre-open indication.
CRISPR Therapeutics (CRSP) closed down -$1.87 after Tuesday’s +$3.12 and Monday’s +$0.69 with a positive +$0.87 or +1.36% pre-open indication.
Editas Medicine (EDIT) closed down -$0.92 after Tuesday’s +$1.68 with a positive +$0.48 or +2.46% pre-open indication.
Global Blood Therapeutics (GBT) closed down -$0,54 with a positive +$0.29 or +0.83% pre-open indication
Ionis Pharmaceuticals (IONS) closed down -$0.79 with a positive +$0.87 or +2.445 pre-open indication.

SELL:

Fate Therapeutics (FATE) closed down -$2.08 after Tuesday’s +$3.94 with a negative -$0.86 or -2.61% pre-open indication.
Vericel (VCEL) closed down -$0.36 after Tuesday’s +$2.28 after Monday’s +$1.52 with a negative $0.17 or -0.43% pre-open indication.

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed up +$0.50 with 3,932 shares traded after Tuesday’s -$0.50 with 3,330 shares traded, Monday’s +$0.26 to $5.00 with 13,012 shares traded, Friday’s +$0.44 with 1,978 shares traded and last Thursday’s flat with 34 shares traded. WHY BUY these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?

The BOTTOM LINE: What goes down, eventually bounces from being oversold.

An odd quote that caught my eye and some feelings, “To paraphrase the Rolling Stones, you can't always get what you want, but sometimes you get what you need. The stock market rally can't go up every day, with the key indexes retreating Wednesday. But that's in the context of a rapid ascent for the past few weeks. The Nasdaq hitting resistance near its 200-day moving average is natural.” <IBD>

Although, I’m STILL a firm believer in the flight of Icarus … since the cell and gene therapy equities have oscillated between gains and losses since the first of the year... a bigger “slip” is on the way – maybe NOT today but, it’s coming!

Hold-on (to the railing) as our portfolios weather these volatile sessions as an ordinary practice.

Again, I reiterate, “I’m never totally wrong but, not always wholly right as there is no clear trend ….

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.